However, apart from those specific contexts, PI3K pathway inhibitors generally delivered only modest effects in the clinical setting (Janku et al, 2018), and no clear evidence of benefits for PTEN‐deficient tumor patients has been reported so far (Kim et al, 2017; Martin et al, 2017). The gene discussed is PIK3CA; the disease is neoplasm.